Compound useful for the treatment of degenerative and inflammatory diseases
A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
1. A pharmaceutically acceptable salt of a compound according to Formula I:
wherein said pharmaceutically acceptable salt is a maleic acid salt.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a pharmaceutically acceptable salt of a compound according claim 1 .
3. The pharmaceutical composition according to claim 2 comprising a further therapeutic agent.
4. A method for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders, comprising administering an amount of a pharmaceutically acceptable salt of claim 1 , sufficient to effect said treatment.
5. The method according to claim 4 , wherein the said pharmaceutically acceptable salt is administered in combination with a further therapeutic agent.
6. The pharmaceutical composition according to claim 2 , wherein the further therapeutic agent is an agent for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders.
7. A method for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders, comprising administering an amount of a pharmaceutical composition of claim 2 , sufficient to effect said treatment.
8. A method for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders, comprising administering an amount of a pharmaceutical composition of claim 3 , sufficient to effect said treatment.
9. The method according to claim 7 , wherein the pharmaceutical composition is administered in combination with a further therapeutic agent.
10. The method according to claim 8 , wherein the pharmaceutical composition is administered in combination with a further therapeutic agent.
11. The method according to claim 5 , wherein the further therapeutic agent is an agent for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders.
12. The method according to claim 9 , wherein the further therapeutic agent is an agent for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders.
13. The method according to claim 10 , wherein the further therapeutic agent is an agent for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders.